Copyright Reports & Markets. All rights reserved.

Global and United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 BMS-906024
    • 1.2.3 Buparlisib Hydrochloride
    • 1.2.4 FP-1039
    • 1.2.5 Ipilimumab
    • 1.2.6 JNJ-42756493
    • 1.2.7 Lenvatinib
    • 1.2.8 Others
  • 1.3 Market by Application
    • 1.3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application: 2020 VS 2026
    • 1.3.2 Research Center
    • 1.3.3 Hospital
    • 1.3.4 Clinic
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Perspective (2015-2026)
  • 2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Growth Trends by Regions
    • 2.2.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Share by Regions (2015-2020)
    • 2.2.3 Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Market Size
    • 3.1.1 Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Revenue (2015-2020)
    • 3.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue
  • 3.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio
    • 3.4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2019
  • 3.5 Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Area Served
  • 3.6 Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Product Solution and Service
  • 3.7 Date of Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Type (2015-2026)

  • 4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Type (2015-2020)
  • 4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2021-2026)

5 Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Application (2015-2026)

  • 5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Application (2015-2020)
  • 5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2015-2026)
  • 6.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
  • 6.3 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
  • 6.4 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2015-2026)
  • 7.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
  • 7.3 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
  • 7.4 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2015-2026)
  • 8.2 China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
  • 8.3 China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
  • 8.4 China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2015-2026)
  • 9.2 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
  • 9.3 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
  • 9.4 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2015-2026)
  • 10.2 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Ascenta Therapeutics, Inc.
    • 11.1.1 Ascenta Therapeutics, Inc. Company Details
    • 11.1.2 Ascenta Therapeutics, Inc. Business Overview
    • 11.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 11.1.4 Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020))
    • 11.1.5 Ascenta Therapeutics, Inc. Recent Development
  • 11.2 AstraZeneca Plc
    • 11.2.1 AstraZeneca Plc Company Details
    • 11.2.2 AstraZeneca Plc Business Overview
    • 11.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 11.2.4 AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 11.2.5 AstraZeneca Plc Recent Development
  • 11.3 AVEO Pharmaceuticals, Inc.
    • 11.3.1 AVEO Pharmaceuticals, Inc. Company Details
    • 11.3.2 AVEO Pharmaceuticals, Inc. Business Overview
    • 11.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 11.3.4 AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 11.3.5 AVEO Pharmaceuticals, Inc. Recent Development
  • 11.4 Bayer AG
    • 11.4.1 Bayer AG Company Details
    • 11.4.2 Bayer AG Business Overview
    • 11.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 11.4.4 Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 11.4.5 Bayer AG Recent Development
  • 11.5 BIND Therapeutics, Inc.
    • 11.5.1 BIND Therapeutics, Inc. Company Details
    • 11.5.2 BIND Therapeutics, Inc. Business Overview
    • 11.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 11.5.4 BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 11.5.5 BIND Therapeutics, Inc. Recent Development
  • 11.6 Boehringer Ingelheim GmbH
    • 11.6.1 Boehringer Ingelheim GmbH Company Details
    • 11.6.2 Boehringer Ingelheim GmbH Business Overview
    • 11.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 11.6.4 Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 11.6.5 Boehringer Ingelheim GmbH Recent Development
  • 11.7 Bristol-Myers Squibb Company
    • 11.7.1 Bristol-Myers Squibb Company Company Details
    • 11.7.2 Bristol-Myers Squibb Company Business Overview
    • 11.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 11.7.4 Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 11.7.5 Bristol-Myers Squibb Company Recent Development
  • 11.8 Eli Lilly and Company
    • 11.8.1 Eli Lilly and Company Company Details
    • 11.8.2 Eli Lilly and Company Business Overview
    • 11.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 11.8.4 Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 11.8.5 Eli Lilly and Company Recent Development
  • 11.9 F. Hoffmann-La Roche Ltd.
    • 11.9.1 F. Hoffmann-La Roche Ltd. Company Details
    • 11.9.2 F. Hoffmann-La Roche Ltd. Business Overview
    • 11.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 11.9.4 F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 11.9.5 F. Hoffmann-La Roche Ltd. Recent Development
  • 11.10 Five Prime Therapeutics, Inc.
    • 11.10.1 Five Prime Therapeutics, Inc. Company Details
    • 11.10.2 Five Prime Therapeutics, Inc. Business Overview
    • 11.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 11.10.4 Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 11.10.5 Five Prime Therapeutics, Inc. Recent Development
  • 11.11 Genentech, Inc.
    • 10.11.1 Genentech, Inc. Company Details
    • 10.11.2 Genentech, Inc. Business Overview
    • 10.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 10.11.4 Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 10.11.5 Genentech, Inc. Recent Development
  • 11.12 Incyte Corporation
    • 10.12.1 Incyte Corporation Company Details
    • 10.12.2 Incyte Corporation Business Overview
    • 10.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 10.12.4 Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 10.12.5 Incyte Corporation Recent Development
  • 11.13 Johnson & Johnson
    • 10.13.1 Johnson & Johnson Company Details
    • 10.13.2 Johnson & Johnson Business Overview
    • 10.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 10.13.4 Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 10.13.5 Johnson & Johnson Recent Development
  • 11.14 MacroGenics, Inc.
    • 10.14.1 MacroGenics, Inc. Company Details
    • 10.14.2 MacroGenics, Inc. Business Overview
    • 10.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 10.14.4 MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 10.14.5 MacroGenics, Inc. Recent Development
  • 11.15 Novartis AG
    • 10.15.1 Novartis AG Company Details
    • 10.15.2 Novartis AG Business Overview
    • 10.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 10.15.4 Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 10.15.5 Novartis AG Recent Development
  • 11.16 Oncogenex Pharmaceuticals, Inc.
    • 10.16.1 Oncogenex Pharmaceuticals, Inc. Company Details
    • 10.16.2 Oncogenex Pharmaceuticals, Inc. Business Overview
    • 10.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 10.16.4 Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 10.16.5 Oncogenex Pharmaceuticals, Inc. Recent Development
  • 11.17 PsiOxus Therapeutics Limited
    • 10.17.1 PsiOxus Therapeutics Limited Company Details
    • 10.17.2 PsiOxus Therapeutics Limited Business Overview
    • 10.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
    • 10.17.4 PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 10.17.5 PsiOxus Therapeutics Limited Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Squamous Non-Small Cell Lung Cancer Therapeutics Scope and Market Size
    Squamous Non-Small Cell Lung Cancer Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Squamous Non-Small Cell Lung Cancer Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    BMS-906024
    Buparlisib Hydrochloride
    FP-1039
    Ipilimumab
    JNJ-42756493
    Lenvatinib
    Others

    Market segment by Application, split into
    Research Center
    Hospital
    Clinic

    Based on regional and country-level analysis, the Squamous Non-Small Cell Lung Cancer Therapeutics market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Squamous Non-Small Cell Lung Cancer Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Ascenta Therapeutics, Inc.
    AstraZeneca Plc
    AVEO Pharmaceuticals, Inc.
    Bayer AG
    BIND Therapeutics, Inc.
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd.
    Five Prime Therapeutics, Inc.
    Genentech, Inc.
    Incyte Corporation
    Johnson & Johnson
    MacroGenics, Inc.
    Novartis AG
    Oncogenex Pharmaceuticals, Inc.
    PsiOxus Therapeutics Limited

    Buy now